• Complete access for ReNerve in the Hong Kong market
• Independent review of the safety and effectiveness of the NervAlign® Nerve Cuff
• Positive assessment validates ReNerve pursuing approval in more countries

ReNerve Limited (ASX, 'ReNerve' or 'the Company'), a leading Australian medical device innovator focused on solutions for peripheral nerve injury (PNI), is pleased to announce that its NervAlign® Nerve Cuff has received listing approval in Hong Kong. This facilitates extending previous access to the product to public hospitals as well as the private hospital systems in the Hong Kong region, including facilitating Greater Bay Area hospital access. The review and approval process included assessment of the clinical evaluation report containing data from the clinical studies conducted with the NervAlign® Nerve Cuff, which illustrates its effectiveness in assisting nerve repairs and patient recovery. In addition to providing broader approval, it also provides independent validation of the patient clinical and post-surgery recovery outcomes when used in peripheral nerve repair. ReNerve is currently marketing its NervAlign® Nerve Cuff in the US, Bahrain, New Zealand, Hong Kong and Thailand whilst pursuing approvals in more than 10 further countries. This positive review provides ReNerve with further validation of the effectiveness of Nerve Cuff to support initiating the approval processes in additional countries including Europe.